Trial | NCT00503022  Report issue

Title

Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
A Randomized, Double-Masked, Multi-Center Phase I Study of 6 Months Duration to Assess the Safety and Tolerability of Intravenous ACZ885 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    20
This study evaluates the tolerability and safety of a single intravenous infusion of ACZ885. It also explores the efficacy of the compound in central macular edema and visual acuity in patients with wet age-related macular edema.
Study Started
Jul 31
2006
Last Update
Dec 28
2007
Estimate

Drug ACZ885

Criteria 

Inclusion criteria:

Male or female ≥ 50 years old, with aged related macular degeneration
Patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Exclusion criteria:

Active intraocular inflammation or ocular infection in the study eye
Eye disease that may result in visual loss during the study
Chronic therapy with topical, local or systemic corticosteroids.
Pregnant or nursing (lactating) women.
No Results Posted